Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:46:16.258Z.
Calculation as of: 2026-10-06T14:46:16.258Z.
Quote observation: 2026-10-06T14:44:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc6ba70d6a7a815a92143918ed9b9c2f02635c4477fd12c4733392629ce909df
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$86.59M
EBITDA Yield
N/A
TTM Avg
17.90%
3Y Avg
17.90%
5Y Avg
17.90%
Market Cap
$82.39M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | $85.17M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.58M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.39M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $86.59M | N/A | 17.90% | 17.90% | 17.90% |
| Nutriband Inc. (NTRB)vs › | $86.67M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $87.11M | 21.53% | 23.06% | 41.09% | 38.38% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.39M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $81.55M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.45M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $81.82M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
